Novo Nordisk shares in hot water after disappointing trial

1 hour ago 1

Investors who had hopes that Novo Nordisk (NVO) could win extracurricular of weight-loss drugs were disappointed connected Friday, July 31.

The Danish drugmaker said its experimental bosom cause Ziltivekimab failed the main extremity of a ample late-stage trial, and the banal fell fast.

Novo has spent 2026 trying to beryllium it tin turn beyond Wegovy and Ozempic, and this was 1 of the clearest tests of that plan.

For anyone holding the banal oregon watching the dip, the absorption says a batch astir however overmuch the marketplace had riding connected this trial.

Novo Nordisk banal falls aft its ZEUS bosom cause proceedings misses

Novo Nordisk started July 31 with 1 of its worst trading sessions successful months.

The institution said its bosom cause Ziltivekimab failed the main extremity of the ZEUS trial, and investors sold the banal fast.

Novo Nordisk's Danish shares fell astir 7.5% connected the day, portion the company's U.S.-listed shares dropped 8.6% successful aboriginal trading, CNBC reported.

The driblet shows however overmuch investors were counting connected Ziltivekimab to go a 2nd maturation motor adjacent to Novo's weight-loss and diabetes drugs.

That anticipation is present connected hold, and the banal absorption reflects it.

What the ZEUS proceedings tested and wherefore it failed

ZEUS was a late-stage proceedings that followed more than 6,300 people, according to Novo Nordisk's property release.

The patients had atherosclerotic cardiovascular disease, chronic kidney disease, and ongoing inflammation. That past radical matters due to the fact that inflammation is linked to bosom attacks and strokes.

Ziltivekimab is simply a once-monthly injection that blocks a macromolecule called IL-6, which drives inflammation successful the body.

More Healthcare Stocks:

Goldman Sachs sees penning connected the partition for Eli Lilly stock
UBS powerfully resets Lilly banal target
JPMorgan resets LLY banal people connected cause demand

Novo wanted to amusement that lowering inflammation would besides little the complaint of large adverse cardiovascular events, similar bosom attack, stroke, oregon cardiovascular death.

The cause did little inflammation markers arsenic designed, but that biologic effect did not crook into less bosom events.

The proceedings posted a hazard ratio of 0.99, which means patients connected the cause had astir the aforesaid hazard arsenic patients connected a placebo.

One information item stood out. Patients connected Ziltivekimab had much superior infections than those connected placebo, though wide decease rates were akin betwixt the 2 groups.